• In late May 2026, Labcorp announced a collaboration with the Alliance for Clinical Trials in Oncology on a nationwide colorectal cancer genetics trial and, separately, expanded its DPYD genotyping test to help identify patients at higher risk of severe side effects from fluoropyrimidine chemotherapy.
• Together, these moves underscore Labcorp’s focus on genetics-driven oncology care, positioning its Invitae-based testing and pharmacogenomics portfolio at the center of evolving cancer treatment practices.
• With these advances in colorectal cancer genetics and DPYD testing, we’ll explore how they shape Labcorp’s investment narrative over the coming weeks.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Labcorp Holdings' Investment Narrative?

To own Labcorp, you need to be comfortable with a large, capital-intensive diagnostics business that grows steadily rather than spectacularly, with modest revenue and earnings expansion, a long-standing dividend, and ongoing buybacks supporting returns. The near term story has centered on execution against mid single digit revenue guidance, improving margins, and how the market values that against a mid 20s earnings multiple and only slightly higher consensus price targets. Against that backdrop, the colorectal cancer genetics collaboration and the expanded DPYD test are more about sharpening Labcorp’s oncology and pharmacogenomics profile than moving the financial needle immediately; they reinforce oncology and precision medicine as key product catalysts, but do not obviously change guidance or the debt and return on equity concerns that already sit on investors’ radar.

Yet one structural issue still deserves closer attention from shareholders.

Labcorp Holdings' shares have been on the rise but are still potentially undervalued by 49%. Find out what it's worth.

Exploring Other Perspectives

Three Simply Wall St Community fair values span roughly US$260 to a very large upper estimate, highlighting wide disagreement. Set that against Labcorp’s genetics push, and you can weigh long term oncology potential against balance sheet and return on equity concerns through several different lenses.

Explore 3 other fair value estimates on Labcorp Holdings - why the stock might be worth as much as 95% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Labcorp Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.